| Literature DB >> 33975600 |
Alison Keogh1,2, Kristin Taraldsen3, Brian Caulfield4,5, Beatrix Vereijken3.
Abstract
BACKGROUND: The use of wearable sensor technology to collect patient health data, such as gait and physical activity, offers the potential to transform healthcare research. To maximise the use of wearable devices in practice, it is important that they are usable by, and offer value to, all stakeholders. Although previous research has explored participants' opinions of devices, to date, limited studies have explored the experiences and opinions of the researchers who use and implement them. Researchers offer a unique insight into wearable devices as they may have access to multiple devices and cohorts, and thus gain a thorough understanding as to how and where this area needs to progress. Therefore, the aim of this study was to explore the experiences and opinions of researchers from academic, industry and clinical contexts, in the use of wearable devices to measure gait and physical activity.Entities:
Keywords: Accelerometry; Acceptability; Qualitative; Remote monitoring; Wearable devices
Year: 2021 PMID: 33975600 PMCID: PMC8111746 DOI: 10.1186/s12984-021-00874-8
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Participant details
| Variable | |
|---|---|
| Gender | |
| Male (n = ; %) | 7 (35.0%) |
| Female (n = ; %) | 13 (65.0%) |
| Professional role | |
| Clinical academic | 2 (10.0%) |
| Post-doctoral researcher | 3 (15.0%) |
| Professor | 7 (35.0%) |
| Researchera | 5 (25.0%) |
| 1 (5.0%) | |
| 2 (10.0%) | |
| Country of work | |
| Belgium | 1 (5.0%) |
| Germany | 2 (10.0%) |
| Ireland | 2 (10.0%) |
| Israel | 1 (5.0%) |
| Italy | 1 (5.0%) |
| Norway | 3 (15.0%) |
| Spain | 2 (10.0%) |
| Switzerland | 1 (5.0%) |
| United Kingdom | 7 (35.0%) |
| Years in research (median, IQR; min–max) | 11.5 (10.5; 4–31) |
| Years experience with wearable devices (median, IQR; min–max) | 9.0 (7.0; 1–20) |
| Background area of study (prior to current role) | |
| Biomedical science | 2 (10.0%) |
| Computer science | 1 (5.0%) |
| Doctor | 4 (20.0%) |
| Engineering | 3 (15.0%) |
| Information technology | 1 (5.0%) |
| Physiology and/or sport and movement science | 4 (20.0%) |
| Physiotherapy | 5 (25.0%) |
| A list of devices/manufacturers that researchers had experience withb | |
| Actibelt; Activpal; Actigraph; Axivity; Biovotion; GaitUp; Hexoskin; Fitbit; Mc10; McRoberts; Movisense; Noraxon; Philips; SenseEye; Sensewear; Shimmer; Strive; Spire, Withings | |
aResearcher denotes senior researchers, project co-ordinators, and/or research associates; blist is not exhaustive as not all researchers could remember all devices they had used, therefore devices are listed by name only and not how many researchers mentioned them, so as to avoid any suggestion of device popularity
Coding process
| Step 1 | Rater 1 read all de-identified texts twice (AK) |
|---|---|
| Familiarisation | Notes taken to manually develop an initial coding book |
| Draft 1 developed by Rater 1 (AK) | |
Step 2 Coding book development | Draft 1 of coding book, plus a single, de-identified text, sent to Rater 2 (KT) |
| Coding book refined by AK and KT | |
| Draft 2 of coding book sent to Rater 3 (BV) | |
Another de-identified text emailed to all coders All raters manually coded this text with Draft 2 | |
| Online meeting held between raters to refine coding book through discussion | |
| Final version of coding book confirmed | |
Step 3 Final coding process | Final version of coding book, plus remaining de-identified texts emailed to all raters Final version of coding book used to manually code all texts (Additional file |
| Rater 1 (AK) coded all texts (n = 20) | |
| Raters 2 and 3 (KT and BV) coded four additional texts each (n = 8) |
Fig. 1Representative mind map
Supporting quotations for Theme 1 ‘the positives and negatives of using wearable devices in research’
| Theme 1: The positives and negatives of using wearable devices in research |
|---|
| “I’ve seen myself from my own experience in a number of trials is that the more ill the individuals are, or the more let’s say, not more degenerative the disease or the more advanced it is or whatever, they feel like if they thought that something could benefit this, even though we always explain that you are not going to directly benefit from this but this research might benefit people in similar situations, then they do feel, like willing to participate.”—Participant 6, Male, Academic |
| “So, the positives with wearables in general is that you can use them wherever you want. So if you are not too keen about using magnetometers then what you can do is you can literally use them anywhere and they are so small that you can, that you can, eh put them on shoes and on human bodies without them being invasive or annoying to them, to patients and also to eh to the people that are doing the experiment.”—Participant 1, Male, Academic |
| “Now I know, okay, another problem is that we, so we do not know a lot about certain diagnosis and how they perform in a way in the home environment. We know as clinicians a lot about how people perform in the hospital and the doctor's practice but we do not know what they do in the home environment. So we are not aware of many symptoms that may exist and do exist but we have never seen them, we have never understood them as medical professionals and the questionnaires, they do not help us with that because the questionnaires have all to be designed by medical doctors and neuropsychologists etc. who have seen the patients in the professional environment. So they cannot ask for these symptoms because only if patients have an understanding of the symptoms by themselves. In Parkinson’s Disease for example, I have the impression that we see entirely new symptoms with this new trend in getting into the home environment which we have never seen in the hospital. This is also something which is a real paradigm shift or paradigm change in the management of diseases for doctors. And you know that it means also for doctors a new understanding of how we manage our patients and we are not yet there with this paradigm shift with regard to how we have to get use of this new technology. It is not only the technology which we need to have a better understanding of something, you need the people, that they accept that there is something new around and that it doesn't solve everything.”—Participant 16, Male, Academic |
| “But that is for me where it is a game changer, the fact that you can really, it’s a discovery, it is what it allows you to do and you can measure things on 100 s of patients rather than on 10 patients and that is still on the clinical research side. On the real life monitoring as I said for me, is this… I believe in the power of going out of the lab and seeing the other dimension, the one that you don't see in the lab. So what does my patient do when they go home?”—Participant 5, Female, Academic |
| “And I think one challenge is really combining them all, so if you could help ahead of time to think through, ok how can we combine the different output files so that we can get, maximise the analysis that we can do on these files. I think that would be something that would be really helpful.”—Participant 3, Female, Academic |
| “People don't realise always that when we say you can take it off after one week that they are done and they throw it away so they don't remember to send it to us or bring it back to us.”—Participant 8, Female, Academic |
Supporting quotations for Theme 2 ‘the routine implementation of wearables into research and clinical practice
| Theme 2: the routine implementation of wearables into research and clinical practice |
|---|
| “That is indeed a problem because I am the reviewer of many papers and I see … of fantastic technical backbone but I see that it does not make sense from a clinical point of view, what they want to measure. Or maybe it is not useful but it does not make sense with regard to quality of life or whatever and the other way around. So when clinicians are measuring it is often obvious that the technology background is missing. So at least in my view the most important aspect is that the relevant stakeholders are sitting together, they try to understand each other's language and everyone is bringing every argument why something should work or should not work and why it is important or why it is not important.”—Participant 16, Male, Academic |
| “An interesting part in this sense is also the clinicians' expectations because there are so many times, I mean of course the clinicians I interact with are involved in research somehow and they are a different species but what happens to me is when I talk to a lot of consultants in the hospital for example they come to me and they are like, fantastic let's go and look at what happens to the patients in the house. And then when you ask them why, so what is the information that you want? They haven’t a clue. So they know that they want something but what will they do with that information? To me it is not that clear”—Participant 5, Female, Academic |
| “Certainly, for COPD which is my area, home monitoring so far for clinical purposes has been a complete dud. Eh well because the things that you can measure, oxygen saturation, heart rate, spirometry those kind of things are just, do not produce, they don’t influence clinical decision making in a positive way..… it’s just that the current technology and the current framework just isn’t there”—Participant 19, Male, Academic |
| “I think typically we are less, most of the human factors reasons we end up losing data not on the patient side but on the investigator side where you know….that’s another thing. You could arguably say that that’s one of the potential pitfalls of this, you know, the ubiquity of sensors, and it’s that when you bring a new researcher into a motion capture laboratory and they see the CODA system and they go wow that’s amazing. I’m going to have to get training so I can use that. I’m not going to be able to just come in, turn it on and figure it out. Whereas when they see a sensor they’re often like oh well that’s pretty easy you know, and frequently it’s not. Frequently there are you know again we’ve had so many times where somebody has put Shimmer on upside down, we’ve had so many times where somebody has forgotten to calibrate a sensor or you know things like that, they didn’t remember that the last person that used it before them was doing some jumping studies and the accelerometer range was completely different than they needed.”—Participant 4, Male, Academic |
| “That I don't know actually because I am not that software engineer so sometimes you upload the data directly to their service and from a clinical point of view you then look into the reports as soon as they are processed. Also because we are not that proficient with the scripting and the algorithms we tried to stay away from that as well, because you don't have enough background, you don't trust yourself fully enough.”—Participant 14, Female, Clinician |
| “No I’ve got a multi-disciplinary team, I’ve got 20 people in my group, half of which will be engineers of different engineering disciplines as well as computer scientists, mathematicians, clinicians, movement scientists. And I deliberately set up my team because I wanted to work with wearable sensors so that was a very deliberate choice.”—Participant 12, Female, Academic |
| “And of course from a clinical point of view sometimes you think that is not that difficult, you just turn your signal upside down or make the absolute values and then everything is going but of course from an engineering point of view that is not always the case”—Participant 13, Male, Academic |
Supporting quotations for Theme 3 ‘the importance of compromise in protocols’
| Theme 3: the importance of compromise in protocols |
|---|
| “So the arm ones weren’t as accurate as the trunk ones ehm, so it comes back because you know there are things that you can wear on your wrist, eh which is more natural as people are used to wearing watches. So eh, you know in some situations for much more prolonged wearing that might be preferable but you know you’re going to have to be careful because you’re going to be losing some sort of precision particularly around walking”—Participant 19, Male, Academic |
| “What can we do to minimise the burden to the participant? But it has to be counter balanced with, we want data of this quality so we’re clear of what we need from the device so it’s that balancing act. And in using the devices that we have, we know that they’re not perfect but we have chosen to eh, we can accept the compromise and still get data that. Gives us good information.”—Participant 12, Female, Academic |
| “Even if it’s some small vendor who is not part of the preferred vendor list of the company and we try to find the best fit. If that’s not possible, too expensive, you know too many GDPR issues, we sort of downgrade and say ok what’s the bare minimum we need and sort of to be, it’s almost a bit cynical but in the end its very often ‘ok, we’ll just stick an Actigraph to the non-dominant wrist’. We find ok at the beginning you said you wanted specific gait parameters, you can’t do that if you stick an Actigraph to the non-dominant wrist, eh so either we do it properly or we don’t do it at all and I think that’s also important that if we deviate too much from what we want we have to say no otherwise we’ll do too much harm to ourselves.”—Participant 17, Male, Industry |
| “If we are just talking about research and we need to push through a high number of patients while all the patients are in the clinic, then I would go for an easy system that is easy to use for the people that do the data collection so in our case medical students for example and then that would be a different system so I cannot really say which system is best because it really depends on what you want. This is why in XX for example we often end up with multiple systems that we are using for multiple things so if we are going for home assessment we are using a different brand than we are using for an in-clinic assessment.”—Participant 1, Male, Academic |
Supporting quotations for Theme 4 ‘securing good quality data’
| Securing good quality data |
|---|
| “I have an information sheet of how to wear and then I go through it with the patient, I go through the importance of it, why we use it, why we need it for seven days, those sorts of things.”—Participant 8, Female, Academic |
| “I think we have better compliance because we’ve got pretty good protocols and data quality checking methods and very robust processes to follow up trial participants or the assessors that are putting the devices on pretty quickly so that we don’t leave six months of data and then go oh by the way we better have a look at that data and see if it’s ok [laughs]. We’re onto it straight away.”—Participant 12, Female, Academic |
| “What we usually do in our clinical studies is we make a very easy to use booklet with figures and then also the first time is that we ourselves apply the systems and we tell in this case if it is the therapist or the patient on what they should be aware of. And we also point them in the booklet that they get so the small brochure for instance where they can find this information. And then next we let them apply everything and just see if they do it correctly and if not then we correct them. Because sometimes you don't think to mention something and you see the patient is doing that and you can intervene.”—Participant 13, Male, Academic |
| “The friendly trials for us are really just a confirmation that what we’re doing is you know, is good, has sound logic behind it and in practice it could work.”—Participant 6, Male, Academic |
| “The challenge is that there are no guidance on what measures to use. So there is a great variability in reported measures so it is not easy to compare between different studies. And that is a challenge I think.”—Participant 11, Female, Researcher |
| “There’s no standard”—Participant 4, Male, Academic |
| “And also if something is going to work it’s probably going to be about integrating different measures. So if you measure how much someone is breathing and how much they’re moving you can pick up different patterns of, you know if someone is keeping still and breathing more that’s bad, if someone is keeping still and not breathing they might have just decided that they’re going to have a Netflix binge. Eh so it’s you know, so far we haven’t got the sort of level of integration, it’s monitoring but not what we need.”—Participant 19, Male, Academic |
| “Yeah because we did validation study in frail populations, we had discussions also with the company on it so what we decided, when we reported outcome in hip pressure patients, for example we only reported by time and we didn't distinguish between gait and standing because we couldn't detect the gait well enough.”– Participant 9, Female, Academic |
| “Well yes misclassification of activities. I mean I didn’t do it because I was just designing the protocol, but I am aware from literature that misclassification of data is a big problem.”—Participant 2, Female, Academic |
| “We get the raw data….but again it’s a black box. Because they are all very sweet and nice guys but all their validation things if you dig a bit deeper, are very obscure. So I’ve cited this one, they’ve cited me and then we’ve cited each other and this is our validation so it’s like ahhhh cool but I don’t really trust you.”—Participant 1, Male, Academic |
| “I suppose if the patient could see something, if they could see what they are recording or that sort of thing I think patients would be more likely to wear it then, if it had a step counter in the front. Then I think it might encourage them to walk more than they normally do or whatever. But I think that probably would encourage the patients to wear it more.”—Participant 14, Female, Clinician |
| “Because patients really want to, this is my experience, they want to be able to understand their own conditions, particularly if they’ve got chronic, long term health conditions. They really welcome the feedback, you know the feedback that they get is that they see the benefits of these tools. So, and anything that they think can help the doctor, or the nurse or the physiotherapist have better information, that also helps them and might help with their medication adjustment and all the rest of it. They really are sensible actually and see the benefits.”—Participant 12, Female, Academic |
| “I think sometimes people can overegg burden a little. You know my experience is that most people who are getting involved in a research study, they’re doing it because they want to help. They’re not doing it out of a sense of obligation or entitlement. You’re generally working with people who are a little bit more giving, that’s the reason they’re there. And, I think people who are involved in studies would expect to have to have some level of active involvement, it’s not all passive.”—Participant 4, Male, Academic |
| “So I think one of the docmarks that we had a while ago was do not influence the patient or don’t show the number of steps tracked or don’t show anything just stick a wearable to them. Now, that has changed. I think that you need to give feedback to encourage the patient to continue wearing the wearable. It doesn’t mean that we have to give details or statistics on performance, even just wear time for example. So feedback and sort of monitoring of wearing is in my opinion very important. If the patient wants to know and wants to participate you know if you just stick a black box to the patient who doesn’t interact with it then I think that is not a good idea.”—Participant 17, Male, Industry |
Supporting quotations for Theme 5 ‘a paradigm shift’
| Theme 5: A paradigm shift |
|---|
| “Eh, from the clinical operations perspective at the moment. So let’s say the aim is to make our trials better in terms of faster, more precise, getting better readouts and cheaper. At the moment the reality is a bit different. At the moment they make it slower and have additional patient and in-site burden and makes them more expensive. So we are still sort of working towards the benefits of it. I don’t know, or I wouldn’t say that its necessarily a downside but if this situation continues too long then patients or maybe stakeholder will sort of lose interest sand it will have a bad effect on the field itself. So I think it needs, sort of from the pharma perspective we do need to show very clear impact either on cost, operations or quality of endpoints.”—Participant 17, Male, Industry |
| “I think that there has been a massive, I mean for me it has been interesting to observe in the sense that coming from the technical background, seeing the uptake before these products were actually ready to be out there, for me was the most interesting part of the story. And somehow it is something that reminded me of what happened with motion capture back in the days. Everyone started having these labs where they think that it was just something that you started using and you had all the data that you collected.”—Participant 5, Female, Academic |
| “In my mind the early stages, more of the focus was on the hardware, and then the ehm, after some of the hardware questions kind of started to settle down a bit then it became more about studies that were aimed at validating the capacity of the IMUs or activity sensors to, in particular if we take the IMUs, it’s kind of moved through different ages. It’s gone from that age of ok, can we eh, lets develop on the hardware level first, then let’s see how well we can measure existing gait measures so like spatiotemporal measures of gait etc. in a controlled laboratory environment, to then gradually looking at ok, lets now that we’ve figured out how we can validate it against gold standard for measuring spatiotemporal parameters, now can we see if we can identify any differences associated with this clinical group or that clinical group so we are comparing the groups to the norm, then there’s that evolution into I suppose seeing whether or not we can move the focus of the measurement outside of the laboratory. So, you know, instead of it being another way to capture information within the clinical environment, now can we actually go out to the persons home, and can we have a HCP go to their home and capture that, or can we capture it in a primary care setting or in a physio setting.”—Participant 4, Male, Academic |
| “ I think I’d like to see more, almost more guidance or help, almost from the accelerometer developers in terms of data output and how the researcher can use it right.”—Participant 3, Female, Academic |
| “Keep doing it. As I said we are still in the discovery phase with all this and we can only when we have understood enough will we be able to use it and understand what we can do with it. So for me at the moment it is working well in the sense that as I said we are finding out things that we would not have known before but how to implement those is the next step. For me there is still a lot of opportunities out there.”—Participant 5, Female, Academic |
| “Well we are not the end users or consumers of this, that’s the patient but we are very close to the patient and then there are the other researchers and we can already see that that is a problem and that there is a disconnect. I mean I can already see with some of the conversations with my academic partners, but then with the algorithm they are so vast. I think it is the right thing we are doing. It’s not ideal as I said because we can’t predict the future and if we could that would be great.”—Participant 17, Male, Industry |
| “We’re movement scientists, and I think we should never lose sight of the fact that whilst again we can use laboratory based motion capture systems, and we can use inertial sensors to capture movement, they can create a whole new paradigm of how we measure movement and behaviour but ultimately we should never try and remove the human from the loop.”—Participant 4, Male, Academic |
| “I would say that….they are not a pancea. They are….[laughs], there is this trend that everything needs to be measured and that because we may have so much data, that this is useful and this is better. And for some research questions, a questionnaire or a simple question may be better and there are many important things related to health that an activity monitor wouldn’t measure such as the type of activity for instance. And, I think that it is important to remember that. That sometimes we tend to go for the more complex technology and sometimes you would just need to talk more with the patient and give less devices.”—Participant 10, Female, Academic |